Investing.com - Financial Markets Worldwide

CG Invites Co Ltd (083790)

KOSDAQ
Currency in KRW
2,000
0(0.00%)
Closed·
083790 Scorecard
Full Analysis
Analysts anticipate sales growth in the current year
083790 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Unlock Value
Day's Range
1,9882,025
52 wk Range
1,9003,145
Key Statistics
Edit
Bid/Ask
2,000.00 / 2,005.00
Prev. Close
2,000
Open
2,000
Day's Range
1,988-2,025
52 wk Range
1,900-3,145
Volume
149.85K
Average Volume (3m)
142.57K
1-Year Change
-30.56%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
083790 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Technical Analysis
Strong Sell
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Unlock All 12
Quickly burning through cash
Unlock InvestingPro

CG Invites Co Ltd News & Analysis

No news in this category
Looks like there are no results in this news category

CG Invites Company Profile

CG Invites Co., Ltd., a biopharma company, engages in the discovery and development of structural chemoproteiomics-based drugs in Korea. It offers Acelex (polmacoxib), an anti-inflammatory and pain relief drug, as well as CG-650, an anti-inflammatory drug, currently under phase 1 stage for the treatment of osteoarthritis; CG-651, an anti-inflammatory drug, currently under phase 1 stage for the treatment of neuropathic pain; and CG-652, an anti-inflammatory drug, currently under phase 1 stage for the treatment of rheumatoid arthritis. The company is also involved in the development of Ivaltinostat, an anti-cancer drug, currently under phase 2 stage for the treatment of pancreatic cancer and myelodysplastic syndrome, as well as preclinical stage for the treatment of acute myeloid leukemia and hepatocellular carcinoma; Camrelizumab, an anti-cancer drug, currently under phase 3 stage for the treatment of NSCLC; and Luxeptinib, an anti-cancer drug, currently under phase 1 stage for the treatment of acute myeloid leukemia, chronic lymphocytic leukemia, and non-hodgkin’s lymphoma. In addition, it engages in the development of Nilofabicin, anti-infective drug, currently under phas 1 stage for the treatment of MRSA infection; and Ivaltinostat, currently under phase 1 stage for the treatment of fibrotic and metabolic diseases, such as fibrosis. The company was formerly known as CrystalGenomics Invites Co., LTD. and changed its name to CG Invites Co., Ltd. in April 2024. CG Invites Co., Ltd. was incorporated in 2000 and is headquartered in Seoul, South Korea.

Industry
Pharmaceuticals
Sector
Healthcare
Employees
75
Market
South Korea

Compare 083790 to Peers and Sector

Metrics to compare
083790
Peers
Sector
Relationship
P/E Ratio
−3.0x−5.1x−0.5x
PEG Ratio
2.00−0.050.00
Price/Book
1.6x2.1x2.6x
Price / LTM Sales
21.3x9.4x2.9x
Upside (Analyst Target)
-0.0%50.4%
Fair Value Upside
Unlock20.4%9.1%Unlock

Earnings

Latest Release
Mar 20, 2025
EPS / Forecast
-292.82 / --
Revenue / Forecast
2.74B / --
EPS Revisions
a
a
Unlock
Last 90 days

FAQ

What Is the CG Invites (083790) Stock Price Today?

The CG Invites stock price today is 2,000.00.

What Stock Exchange Does CG Invites Trade On?

CG Invites is listed and trades on the KOSDAQ stock exchange.

What Is the Stock Symbol for CG Invites?

The stock symbol for CG Invites is "083790."

What Is the CG Invites Market Cap?

As of today, CG Invites market cap is 153.79B.

What Is CG Invites's Earnings Per Share (TTM)?

The CG Invites EPS (TTM) is -671.17.

From a Technical Analysis Perspective, Is 083790 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.